Blood · 2001 · 235 citations · 44 references
Life SciencesGeneticsImmunologyImmunogeneticsStem Cell TransplantationTransplant ImmunologyCytokine Gene PolymorphismDonor-recipient CompatibilityGraft-versus-host DiseaseHistocompatibilityHla MatchingTransplantation ImmunogeneticsGraft-versus-host Disease ImmunogeneticsGraft-versus-host Disease PathophysiologyHematopoietic Stem Cell Transplantation ImmunogeneticsHla Matching In TransplantationImmunogenetic MatchingInterleukin-6 Gene PolymorphismsInterleukin-6 Gene Variants
Proinflammatory cytokines including interferon-gamma (IFNgamma), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNFalpha) are implicated in the pathogenesis of acute graft-versus-host disease (aGVHD). Cytokine gene polymorphism is associated with functional differences in cytokine regulation and altered clinical performance in a variety of diseases. Polymorphism in the IFNgammaIntron1 microsatellite (CA)n repeat has been linked with in vitro IFNgamma production and renal transplant rejection. The IL-6(-174)(G/C) single nucleotide polymorphism has been linked to in vitro and in vivo IL-6 production, juvenile chronic arthritis, and renal transplant rejection. This study examined the potential association of GVHD with IFNgamma and IL-6 polymorphisms in 80 sibling bone marrow transplant (BMT) donor/recipient pairs. Patients homozygous for the IFNgammaIntron1 allele 3 had more severe (grade III-IV) aGVHD. Patients possessing the IL-6(-174)G allele had a trend toward higher grades of aGVHD, and those homozygous for the IL-6(-174)G allele were more likely to develop chronic GVHD (cGVHD). The associations of previously identified aGVHD severity-associated cytokine gene polymorphisms (TNFd and IL-10(-1064)) with severe aGVHD were reconfirmed. Logistic regression analysis confirmed the association of severe aGVHD with recipient genotype at IFNgammaIntron1 (odds ratio [OR] 3.92; P =.02), IL-10(-1064) (OR 4.61; P =.026) and TNFd (OR 3.29; P =.039), and that of cGVHD with recipient IL-6(-174) genotype (OR 4.25; P =.007), in addition to age, gender mismatch, and underlying disease. Assessment of cytokine genotype may potentially allow more accurate prediction of GVHD and appropriate adjustment of GVHD prophylaxis, as well as indicating novel areas for future studies of GVHD pathogenesis.
44
Daniel Fishman, Gary Faulds, Rachel Jeffery et al. · Journal of Clinical Investigation · 1998 · 2.2K citations · Full text
Rainer Storb, H. Joachim Deeg, John Whitehead et al. · New England Journal of Medicine · 1986 · 1.5K citations
Medicine, Hematology, Immunology +14